Universal Beteiligungs und Servicegesellschaft mbH Sells 2,101,558 Shares of Lantheus Holdings, Inc. $LNTH

Universal Beteiligungs und Servicegesellschaft mbH trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 97.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 61,714 shares of the medical equipment provider’s stock after selling 2,101,558 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Lantheus were worth $4,112,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Evergreen Capital Management LLC bought a new position in Lantheus during the 4th quarter worth approximately $200,000. Martin Capital Advisors LLP grew its position in shares of Lantheus by 9.2% in the 4th quarter. Martin Capital Advisors LLP now owns 14,166 shares of the medical equipment provider’s stock worth $943,000 after buying an additional 1,188 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 275 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in shares of Lantheus by 6.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 32,596 shares of the medical equipment provider’s stock worth $2,169,000 after buying an additional 1,856 shares during the last quarter. Finally, Blue Trust Inc. grew its position in shares of Lantheus by 30.3% in the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after buying an additional 230 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Trading Down 2.8%

NASDAQ LNTH opened at $81.17 on Thursday. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $108.91. The firm has a market capitalization of $5.28 billion, a PE ratio of 24.09 and a beta of -0.12. The stock’s 50 day moving average is $78.62 and its 200 day moving average is $67.91.

Lantheus (NASDAQ:LNTH – Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The company had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. During the same period in the previous year, the company posted $1.59 earnings per share. The firm’s revenue was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts forecast that Lantheus Holdings, Inc. will post 4.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

LNTH has been the topic of a number of recent analyst reports. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. William Blair reiterated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Wall Street Zen upgraded Lantheus from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 28th. Finally, Mizuho lifted their price objective on Lantheus from $85.00 to $95.00 and gave the stock an “outperform” rating in a research report on Monday, April 13th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $88.86.

View Our Latest Stock Analysis on LNTH

Lantheus Profile

(Free Report)

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Featured Articles

• Five stocks we like better than Lantheus

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).